API | naptumomab estafenatox

naptumomab estafenatox Report issue

Biologics mAb ADC Experimental

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma and renal cell carcinoma. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

naptumomab estafenatox

anatumomab mafenatox

More Chemistry

Pharmacology

Mechanisms of Action:
- Trophoblast glycoprotein (Homo sapiens) ^UniProt
- Trophoblast glycoprotein (Homo sapiens) ^UniProt
Multi-specific: No
Payload: estafenatox
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

abr-217620 | anyara | anyara tts cd3 | naptumomab estafenatox | tts-cd3

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (18)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (18)

Breast Neoplasms (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2/Phase 3)

Carcinoma, Transitional Cell (Phase 1)

Colorectal Neoplasms (Phase 1)

Endometrial Neoplasms (Phase 1)

Esophageal Neoplasms (Phase 1)

Melanoma (Phase 1)

Mesothelioma (Phase 1)

Mutation (Phase 1)

Ovarian Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Uterine Cervical Neoplasms (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue